Roche wins key lung cancer combo approval

Dec 07, 2018

Roche Holding’s Tecentriq immunotherapy, in combination with Avastin and chemotherapy, won U.S. FDA approval as a first-line treatment for a type of lung cancer.

The approval was based on results from a late-stage study, which showed the Tecentriq regimen helped patients with metastatic non-squamous non-small cell lung cancer (NSCLC) live significantly longer, compared with Avastin and chemotherapy.

Tecentriq is already approved in the U.S. to treat certain types of lung cancers, as well as a type of bladder and urinary tract cancer.

The newly-approved regimen—containing Tecentriq, Roche's older blockbuster, Avastin and chemotherapy— will now face up against rival Merck’s Keytruda.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments